Corcept Therapeutics Inc. (NASDAQ:CORT) is one of the 10 Stocks Investors Are Buying Now. Corcept Therapeutics rallied for a second day on Wednesday, soaring 19.66 percent to finish at $40.47 apiece, as investors snapped up shares after securing the green light of the Food and Drug Administration (FDA) to sell its ovarian cancer treatment, Lifyorli. In an updated report, Corcept Therapeutics Inc. (NASDAQ:CORT) said that the approval was based on the success of its clinical trial, which enrolled 381 patie ...